Hims & Hers Health (NYSE:HIMS) Releases Earnings Results, Beats Estimates By $0.02 EPS

Hims & Hers Health (NYSE:HIMS) posted its quarterly earnings results on Monday. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02, Briefing.com reports. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. Hims & Hers Health’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.03) earnings per share.

Hims & Hers Health Trading Down 2.5 %

HIMS stock traded down $0.42 during trading on Wednesday, hitting $16.46. The company had a trading volume of 7,031,663 shares, compared to its average volume of 7,791,755. The stock has a market cap of $3.54 billion, a PE ratio of -1,624.00 and a beta of 1.08. The business has a 50-day moving average of $21.35 and a 200-day moving average of $15.86. Hims & Hers Health has a one year low of $5.65 and a one year high of $25.74.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective on the stock. Piper Sandler reissued a “neutral” rating and set a $18.00 price target on shares of Hims & Hers Health in a report on Tuesday. TD Cowen upped their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Truist Financial lifted their target price on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Finally, Jefferies Financial Group increased their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.07.

Insiders Place Their Bets

In related news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $22.00, for a total value of $45,188.00. Following the transaction, the insider now owns 185,326 shares in the company, valued at $4,077,172. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the completion of the sale, the insider now directly owns 185,326 shares in the company, valued at $4,077,172. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 10,000 shares of the stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $13.00, for a total value of $130,000.00. Following the transaction, the insider now owns 173,880 shares in the company, valued at $2,260,440. The disclosure for this sale can be found here. In the last 90 days, insiders sold 782,901 shares of company stock worth $16,138,997. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.